Piperacillin-Tazobactam Compared With Cefoxitin as Antimicrobial Prophylaxis for Pancreatoduodenectomy
JAMA · 09.05.2023 · 329 (18) · 1579
DOI: 10.1001/jama.2023.5728 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, erschienen am 09.05.2023. Verfasst von Michael I D'Angelica und 36 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center, New York, New York. Hauptthemen laut MEDLINE: Cefoxitin, Sepsis. Die Arbeit wurde bisher 133-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Importance Despite improvements in perioperative mortality, the incidence of postoperative surgical site infection (SSI) remains high after pancreatoduodenectomy. The effect of broad-spectrum antimicrobial surgical prophylaxis in reducing SSI is poorly understood.
Objective
To define the effect of broad-spectrum perioperative antimicrobial prophylaxis on postoperative SSI incidence compared with standard care antibiotics. Design, Setting, and Participants Pragmatic, open-label, multicenter, randomized phase 3 clinical trial at 26 hospitals across the US and Canada. Participants were enrolled between November 2017 and August 2021, with follow-up through December 2021. Adults undergoing open pancreatoduodenectomy for any indication were eligible. Individuals were excluded if they had allergies to study medications, active infections, chronic steroid use, significant kidney dysfunction, or were pregnant or breastfeeding. Participants were block randomized in a 1:1 ratio and stratified by the presence of a preoperative biliary stent. Participants, investigators, and statisticians analyzing trial data were unblinded to treatment assignment.
Intervention
The intervention group received piperacillin-tazobactam (3.375 or 4 g intravenously) as perioperative antimicrobial prophylaxis, while the control group received cefoxitin (2 g intravenously; standard care). Main Outcomes and Measures The primary outcome was development of postoperative SSI within 30 days. Secondary end points included 30-day mortality, development of clinically relevant postoperative pancreatic fistula, and sepsis. All data were collected as part of the American College of Surgeons National Surgical Quality Improvement Program.
Results
The trial was terminated at an interim analysis on the basis of a predefined stopping rule. Of 778 participants (378 in the piperacillin-tazobactam group [median age, 66.8 y; 233 {61.6%} men] and 400 in the cefoxitin group [median age, 68.0 y; 223 {55.8%} men]), the percentage with SSI at 30 days was lower in the perioperative piperacillin-tazobactam vs cefoxitin group (19.8% vs 32.8%; absolute difference, −13.0% [95% CI, −19.1% to −6.9%]; P < .001). Participants treated with piperacillin-tazobactam, vs cefoxitin, had lower rates of postoperative sepsis (4.2% vs 7.5%; difference, −3.3% [95% CI, −6.6% to 0.0%]; P = .02) and clinically relevant postoperative pancreatic fistula (12.7% vs 19.0%; difference, −6.3% [95% CI, −11.4% to −1.2%]; P = .03). Mortality rates at 30 days were 1.3% (5/378) among participants treated with piperacillin-tazobactam and 2.5% (10/400) among those receiving cefoxitin (difference, −1.2% [95% CI, −3.1% to 0.7%]; P = .32). Conclusions and Relevance In participants undergoing open pancreatoduodenectomy, use of piperacillin-tazobactam as perioperative prophylaxis reduced postoperative SSI, pancreatic fistula, and multiple downstream sequelae of SSI. The findings support the use of piperacillin-tazobactam as standard care for open pancreatoduodenectomy. Trial Registration ClinicalTrials.gov Identifier: NCT03269994
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Memorial Sloan Kettering Cancer Center, New York, New York.
- American College of Surgeons, Chicago, Illinois.
- Brigham and Women's Hospital, Boston, Massachusetts.
- The Oregon Clinic/Providence Portland Medical Center, Portland.
- Northwestern University, Chicago, Illinois.
- Baptist Memorial Medical Education, Memphis, Tennessee.
Förderung
- NCI NIH HHS
Zitieren
APA
D'Angelica, M. I., Ellis, R. J., Liu, J. B., Brajcich, B. C., Gönen, M., Thompson, V. M., Cohen, M. E., Seo, S. K., Zabor, E. C., Babicky, M. L., Bentrem, D. J., Behrman, S. W., Bertens, K. A., Celinski, S. A., Chan, C. H. F., Dillhoff, M., Dixon, M. E. B., Fernandez-Del Castillo, C., Gholami, S., …, & Ko, C. Y. (2023). Piperacillin-Tazobactam Compared With Cefoxitin as Antimicrobial Prophylaxis for Pancreatoduodenectomy. JAMA, 329(18), 1579. https://doi.org/10.1001/jama.2023.5728
Vancouver
D'Angelica MI, Ellis RJ, Liu JB, Brajcich BC, Gönen M, Thompson VM, et al. Piperacillin-Tazobactam Compared With Cefoxitin as Antimicrobial Prophylaxis for Pancreatoduodenectomy. JAMA. 2023;329(18):1579. doi:10.1001/jama.2023.5728
BibTeX
@article{DAngelica2023,
author = {D'Angelica, Michael I and Ellis, Ryan J and Liu, Jason B and Brajcich, Brian C and Gönen, Mithat and Thompson, Vanessa M and Cohen, Mark E and Seo, Susan K and Zabor, Emily C and Babicky, Michele L and Bentrem, David J and Behrman, Stephen W and Bertens, Kimberly A and Celinski, Scott A and Chan, Carlos H F and Dillhoff, Mary and Dixon, Matthew E B and Fernandez-Del Castillo, Carlos and Gholami, Sepideh and House, Michael G and Karanicolas, Paul J and Lavu, Harish and Maithel, Shishir K and McAuliffe, John C and Ott, Mark J and Reames, Bradley N and Sanford, Dominic E and Sarpel, Umut and Scaife, Courtney L and Serrano, Pablo E and Smith, Travis and Snyder, Rebecca A and Talamonti, Mark S and Weber, Sharon M and Yopp, Adam C and Pitt, Henry A and Ko, Clifford Y},
title = {Piperacillin-Tazobactam Compared With Cefoxitin as Antimicrobial Prophylaxis for Pancreatoduodenectomy},
journal = {JAMA},
year = {2023},
volume = {329},
number = {18},
pages = {1579},
doi = {10.1001/jama.2023.5728}
}
EUVIMED